602 / 1726
GUSTAVE ROUSSY
THÈME DU DIAPORAMA
- 60 patients from 25 institutions were enrolled between 2006 and 2009
- 49 patients evaluable
- Median follow-up time 3.8 years (Mostly IIB 63%, squamous-80% )
- There were 15 (31%) protocol specified treatment-related AEs, most common were
hematologic (12/15 =80
- 3-year OS 81%, DFS 67%, LRF 23%
BIOLOGIC AGENTS -
BEVACIZUMAB
Phase II study of Bevacizumab in combination with
definitive radiotherapy and cisplatin in locally advanced cervical carcinoma
(RTOG 0417)
Int J Radiat Oncol Biol Phys 88:101-5; 2014